Unit of Endocrinology, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
Pediatric Endocrinology Unit, Department of Mother and Child, University Hospital Federico II, European Reference Network on Rare Endocrine Conditions (Endo-ERN), Center for Rare Endocrine Conditions, Naples, Italy.
Front Endocrinol (Lausanne). 2023 Feb 13;14:1133376. doi: 10.3389/fendo.2023.1133376. eCollection 2023.
Despite the optimization of replacement therapy, adrenal crises still represent life-threatening emergencies in many children with adrenal insufficiency.
We summarized current standards of clinical practice for adrenal crisis and investigated the prevalence of suspected/incipient adrenal crisis, in relation to different treatment modalities, in a group of children with adrenal insufficiency.
Fifty-one children were investigated. Forty-one patients (32 patients <4 yrs and 9 patients >4 yrs) used quartered non-diluted 10 mg tablets. Two patients <4 yrs used a micronized weighted formulation obtained from 10 mg tablets. Two patients <4 yrs used a liquid formulation. Six patients >4 yrs used crushed non-diluted 10 mg tablets. The overall number of episodes of adrenal crisis was 7.3/patient/yr in patients <4yrs and 4.9/patient/yr in patients >4 yrs. The mean number of hospital admissions was 0.5/patient/yr in children <4 yrs and 0.53/patient/yr in children >4 yrs. There was a wide variability in the individual number of events reported. Both children on therapy with a micronized weighted formulation reported no episode of suspected adrenal crisis during the 6-month observation period.
Parental education on oral stress dosing and switching to parenteral hydrocortisone when necessary are the essential approaches to prevent adrenal crisis in children.
尽管替代疗法已经得到优化,但在许多患有肾上腺功能不全的儿童中,肾上腺危象仍然是危及生命的紧急情况。
我们总结了目前肾上腺危象的临床实践标准,并调查了一组肾上腺功能不全儿童中,不同治疗方式与疑似/初期肾上腺危象的患病率之间的关系。
共调查了 51 名儿童。41 名患者(32 名<4 岁,9 名>4 岁)使用四分之一未经稀释的 10mg 片剂。2 名<4 岁的患者使用从 10mg 片剂获得的微粉化称重制剂。2 名<4 岁的患者使用液体制剂。6 名>4 岁的患者使用未稀释的 10mg 片剂粉碎。<4 岁的患者每年发生肾上腺危象的次数为 7.3/人,>4 岁的患者为 4.9/人。<4 岁的儿童每年因肾上腺危象住院的平均次数为 0.5/人,>4 岁的儿童为 0.53/人。报告的个体事件数量存在很大差异。使用微粉化称重制剂治疗的两名儿童在 6 个月的观察期间均未报告疑似肾上腺危象发作。
对父母进行口服应激剂量和必要时转为静脉用氢化可的松的教育是预防儿童肾上腺危象的重要方法。